Insulin oral sublingual - Albireo Pharma

Drug Profile

Insulin oral sublingual - Albireo Pharma

Alternative Names: VIAtab

Latest Information Update: 12 Jan 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Biodel
  • Developer Albireo Pharma
  • Class Antihyperglycaemics; Insulins; Pancreatic hormones
  • Mechanism of Action Ornithine decarboxylase stimulants; Phosphokinase stimulants; Protein tyrosine kinase stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I Type 1 diabetes mellitus

Most Recent Events

  • 24 Jul 2013 Biomarkers information updated
  • 03 Feb 2011 Biodel announces its decision to limit funding to its early stage development programmes, including a sublingual insulin formulation
  • 02 Nov 2010 Phase-I development is ongoing in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top